101258-16-6

Basic information

• Product Name: 1-(2-AMINO-1,3-THIAZOL-4-YL)ETHANONE
• Synonyms: Ethanone,1-(2-aMino-4-thiazolyl)-;1-(2-amino-4-thiazolyl)ethanone;Ketone 2-amino-4-thiazolyl methyl
• CAS NO: 101258-16-6
• Molecular Formula: C₅H₆N₂OS
• Molecular Weight: 142.18
• Mol File: 101258-16-6.mol

Chemical Properties

• Melting Point: 230 °C
• Boiling Point: 303.1°Cat760mmHg
• Flash Point: 137.1°C
• Appearance: white powder
• Density: 1.341g/cm³
• Vapor Pressure: 0.000948mmHg at 25°C
• Refractive Index: 1.615
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.41±0.10(Predicted)
• CAS DataBase Reference: 1-(2-AMINO-1,3-THIAZOL-4-YL)ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-AMINO-1,3-THIAZOL-4-YL)ETHANONE(101258-16-6)
• EPA Substance Registry System: 1-(2-AMINO-1,3-THIAZOL-4-YL)ETHANONE(101258-16-6)

Safety Data

• Hazardous Substances Data: 101258-16-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Amino-1,3-thiazol-4-yl)ethanone is used as a key intermediate in the synthesis of various pharmaceuticals for its wide range of biological activities. It contributes to the development of new drugs with potential therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(2-Amino-1,3-thiazol-4-yl)ethanone serves as a building block in the synthesis of agrochemicals, such as pesticides and herbicides, due to its versatile chemical properties and potential biological activities.
Used in Chemical Research:
1-(2-Amino-1,3-thiazol-4-yl)ethanone is used as a research compound for studying thiazole-containing compounds and their potential applications in medicine and agriculture. It aids in understanding the structure-activity relationships and exploring new synthetic routes for the development of novel therapeutic agents.
Used in Food and Beverage Industry:
In the food and beverage industry, 1-(2-Amino-1,3-thiazol-4-yl)ethanone is used as a flavor or fragrance ingredient, adding unique taste and aroma profiles to various products. Its application in this industry highlights its potential for enhancing consumer experiences and product differentiation.

InChI:InChI=1/C5H6N2OS/c1-3(8)4-2-9-5(6)7-4/h2H,1H3,(H2,6,7)

Upstream product

• 17356-08-0 thiourea 
• 431-03-8 dimethylglyoxal 
• 5308-51-0 1-bromobutane-2,3-dione 
• 116008-78-7 1-(2-amino-thiazol-4-yl)-ethanone; hydrochloride 
• 762271-84-1 (4-Acetyl-thiazol-2-yl)-carbamic acid tert-butyl ester 
• 5559-62-6 1-chloro-2,3-dioxo-butane 

Downstream Products

• 876754-81-3 [(1S,2S)-1-(4-acetyl-thiazol-2-ylcarbamoyl)-2-phenyl-propyl]-carbamic acid tert-butyl ester 
• 1187540-89-1 N-{1-[2-(cyclopropylethynyl)-1,3-thiazol-4-yl]ethoxy}-1-(1-methyl-1H-tetrazol-5-yl)-1-phenylmethanimine 
• 1187540-88-0 N-[1-(2-bromo-1,3-thiazol-4-yl)ethoxy]-1-(1-methyl-1H-tetrazol-5-yl)-1-phenylmethanimine 

Relevant articles and documents

Hitting a Moving Target: Simulation and Crystallography Study of ATAD2 Bromodomain Blockers

Small molecule ligand binding to the ATAD2 bromodomain is investigated here through the synergistic combination of molecular dynamics and protein crystallography. A previously unexplored conformation of the binding pocket upon rearrangement of the gatekeeper residue Ile1074 has been found. Further, our investigations reveal how minor structural differences in the ligands result in binding with different plasticity of the ZA loop for this difficult-to-drug bromodomain.

Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease

Disclosed herein are sulfonamide compounds of Formula VII as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders, polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, cardiovascular conditions, and disorders in which angiogenesis play a role in pathogenesis, using the compounds of the invention. In addition, methods of modulating the activity of histone deacetylase (HDAC) are also disclosed.

Substituted hydantoins

The present invention relates to compounds of the formula which are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as, cancer, cognative and CNS disorders and inflammatory/autoimmune diseases.

NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES

The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X1 represents a nitrogen atom, sulfur atom, oxygen at